期刊文献+

肿瘤坏死因子诱导肿瘤细胞凋亡及其调节机制的研究(英文) 被引量:4

Mechanism of tumor cell apoptosis induced by tumor necrosis factor
在线阅读 下载PDF
导出
摘要 背景肿瘤坏死因子(TNF)在体外能诱导某些正常细胞和大多数肿瘤细胞株(包括Hela细胞株)凋亡,其凋亡发生机制与细胞周期的关系中尚有许多问题需要探讨。目的研究细胞周期时相对TNF诱导Hela细胞凋亡的影响。设计非随机非对照实验研究。地点和对象实验在广东医学院生物化学与分子生物学研究所完成,对象为重组人肿瘤坏死因子-α(rhTNF-α,Sigma产品),Hela细胞株引自中国科学院上海细胞生物研究所。干预通过胸腺嘧啶核苷酸(TdR)阻断法阻滞Hela细胞的细胞周期,采用MTT法、流式细胞术和荧光染色分析TdR阻滞细胞和周期化的Hela细胞对TNF诱导凋亡的敏感性。主要观察指标TNF诱导TdR阻滞和周期化Hela细胞凋亡数。结果TdR阻滞细胞周期较周期化的Hela细胞对TNF诱导凋亡的敏感性降低。结论TNF诱导Hela细胞凋亡与细胞周期有关。 BACKGROUND:Previous researches had confirmed that TNF in vitro could induce apoptosis in some of normal cells and most tumor cells including Hela cell.Some problems between mechnism of apoptosis and relationship of cell cycle should be explored.OBJECTIVE:To study the effect of cell cycle in Hela cells on apoptosis induced by tumor necrosis factor.DESIGN:Nonrandomised uncontrolled study was adopted.SETTING and PARTICIPANTS:The study was completed in the Department of Biochemistry and Molecular Biology of Guangdong Medicine College.Recombinated human TNF α(rhTNF α)was provided by Sigma Co.Hela cells were derived from Cellular Biological Institute of Science Academy of China in Shanghai.INTERVENTIONS:Hela cells was arrested by cell cycle blocking drug [(3H)Thymidine Deoxyribose(TdR)].Hela cells in arresting and cycling were treated with tumor necrosis factor. Cell apoptosis was evaluated by MTT assay, flow cytometry and fluorescent staining.MAIN OUTCOME MEASURE:Blocks of cell cycle by TNF and the apoptosis number of Hela cells were measured.RESULTS:Hela cells by cell cycle arrest became lower sensitive to TNF induced apoptosis.CONCLUSION: Hela cells to apoptosis induced by tumor necrosis factor is related to cell cycle.
出处 《中国临床康复》 CSCD 2004年第23期4918-4919,F003,共3页 Chinese Journal of Clinical Rehabilitation
基金 广东省重点学科经费资助项目(9608)~~
  • 相关文献

参考文献3

二级参考文献15

共引文献50

同被引文献47

  • 1杨勤.阿司匹林对乳腺癌细胞株的抑制作用[J].贵阳医学院学报,2001,26(2):120-121. 被引量:5
  • 2Gibson AD. Rituximab Improves Rate and Duration of Chemotherapy-In-duced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma. Clin Lymphoma 2004;5(2):81-3.
  • 3Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 1999;17(9):2639-48.
  • 4Herbst RS, Hong WK. 1MC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002;29(5 Suppl 14):18-30.
  • 5Eggermont AM, ten Hagen TL.Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 2003;5(2):79-80.
  • 6Morse MA, Clay TM, Lyerly HK. Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther 2002;2(3):237-47.
  • 7Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30(3 Suppl 8):23-9.
  • 8Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003;89(8): 1389-94.
  • 9Kirkwood J.Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002;29(3 Suppl 7):18-26.
  • 10Mey U, Strehl J, Gorschluter M, et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003;4(2):86-94.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部